Suchergebnisse - "Frisell, Thomas"

PubPharm (12)

1

Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs : Results from a 10-year international post-marketing study

enthalten in: Seminars in arthritis and rheumatism | 2024

von Simon, T. | Suissa, S. | Boers, M. | +10

2

Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs : Results from a 10-year international post-marketing study

enthalten in: Seminars in arthritis and rheumatism | 2024

von Simon, T. | Suissa, S. | Skovron, M. | +11

3

Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis : a comprehensive evaluation of randomised controlled trials and observational studies

enthalten in: Annals of the rheumatic diseases | 2024

von Simon, T. | Dong, L. | Suissa, S. | +11

4

Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice : results from the ARTIS programme

enthalten in: Annals of the rheumatic diseases | 2023

von Frisell, T. | Bower, H. | Morin, M. | +21

5

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA : results from a cohort study using nationwide Swedish register data

enthalten in: Rheumatology (Oxford, England) | 2022

von Barbulescu, A. | Askling, J. | Chatzidionysiou, K. | +5

6

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice

enthalten in: Rheumatology (Oxford, England) | 2022

von Huss, V. | Bower, H. | Wadström, H. | +15

CommentIn: Rheumatology (Oxford). 2022 May 5;61(5):1758-1759. - PMID 34648000

7

Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis

enthalten in: The Journal of rheumatology | 2021

von Chatzidionysiou, K. | Hetland, M. | Frisell, T. | +17

8

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

enthalten in: RMD open | 2020

von Chatzidionysiou, K. | Delcoigne, B. | Frisell, T. | +12

9

Comment on : Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply

enthalten in: Rheumatology (Oxford, England) | 2019

von Frisell, T. | Askling, J.

CommentOn: Rheumatology (Oxford). 2019 Jan 21;:null. - PMID 30668875

10

Comment on : Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply

enthalten in: Rheumatology (Oxford, England) | 2019

von Frisell, T. | Askling, J.

CommentOn: Rheumatology (Oxford). 2019 Jan 21;:null. - PMID 30668875